Indian journal of medical microbiology · 2026
Plazomicin susceptibility profile in carbapenem-resistant Enterobacterales (CRE): a laboratory-based cross-sectional study from a tertiary care hospital in North India.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaur Harman Preet, Gautam Hitender, Naskar Tiyasa, Batra Priyam, Mohapatra Sarita, Sood Seema, Dhawan Benu, Das Bimal Kumar
Аннотация
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) represent a major therapeutic challenge, particularly in high-resistance settings where metallo-β-lactamases and aminoglycoside resistance mechanisms may coexist. Plazomicin, a next-generation aminoglycoside designed to evade many aminoglycoside-modifying enzymes, may retain activity against selected CRE isolates; however, its utility in Indian settings remains uncertain.
OBJECTIVES: To evaluate the in vitro susceptibility of CRE isolates to plazomicin and compare its activity with conventional aminoglycosides, including amikacin, gentamicin, and netilmicin, with species-wise and phenotypic subgroup analysis.
METHODS: This laboratory-based cross-sectional study included 106 non-duplicate CRE isolates from a tertiary care centre in North India. Isolates were analysed by specimen source, species distribution, plazomicin susceptibility, comparative aminoglycoside susceptibility, ceftazidime-avibactam (CZA) susceptibility, and ceftazidime-avibactam and aztreonam synergy testing. Statistical comparison of aminoglycoside susceptibility was performed, including paired analysis for Klebsiella pneumoniae using McNemar's exact test.
RESULTS: Among 106 CRE isolates, most were from respiratory specimens 60/106; 56.6%), followed by blood (23/106; 21.7%). Overall, plazomicin susceptibility was 41.5% (44/106), higher than gentamicin (26.4%), amikacin (19.8%), and netilmicin (18.9%), with a statistically significant overall difference (χ2 = 17.80, df = 3, p = 0.00048). Species-wise susceptibility was highest among Escherichia coli (16/27; 59.3%) and lower among Klebsiella pneumoniae (28/76; 36.8%). In K. pneumoniae, paired analysis showed significantly greater susceptibility to plazomicin (36.8%) than gentamicin (19.7%), amikacin (13.2%) and netilmicin (10.5%) with significantly higher paired susceptibility (McNemar exact p < 0.001 for all comparisons). Among ceftazidime-avibactam (CZA) resistant, Aztreonam (AT) synergy-negative E. coli, 6/9 (66.7%) remained plazomicin-susceptible.
CONCLUSION: Plazomicin demonstrated significantly greater in vitro activity than conventional aminoglycosides against CRE, but overall susceptibility remained limited. Its role in high-resistance Indian settings should be selective and guided by phenotypic susceptibility testing rather than empirical use.
OBJECTIVES: To evaluate the in vitro susceptibility of CRE isolates to plazomicin and compare its activity with conventional aminoglycosides, including amikacin, gentamicin, and netilmicin, with species-wise and phenotypic subgroup analysis.
METHODS: This laboratory-based cross-sectional study included 106 non-duplicate CRE isolates from a tertiary care centre in North India. Isolates were analysed by specimen source, species distribution, plazomicin susceptibility, comparative aminoglycoside susceptibility, ceftazidime-avibactam (CZA) susceptibility, and ceftazidime-avibactam and aztreonam synergy testing. Statistical comparison of aminoglycoside susceptibility was performed, including paired analysis for Klebsiella pneumoniae using McNemar's exact test.
RESULTS: Among 106 CRE isolates, most were from respiratory specimens 60/106; 56.6%), followed by blood (23/106; 21.7%). Overall, plazomicin susceptibility was 41.5% (44/106), higher than gentamicin (26.4%), amikacin (19.8%), and netilmicin (18.9%), with a statistically significant overall difference (χ2 = 17.80, df = 3, p = 0.00048). Species-wise susceptibility was highest among Escherichia coli (16/27; 59.3%) and lower among Klebsiella pneumoniae (28/76; 36.8%). In K. pneumoniae, paired analysis showed significantly greater susceptibility to plazomicin (36.8%) than gentamicin (19.7%), amikacin (13.2%) and netilmicin (10.5%) with significantly higher paired susceptibility (McNemar exact p < 0.001 for all comparisons). Among ceftazidime-avibactam (CZA) resistant, Aztreonam (AT) synergy-negative E. coli, 6/9 (66.7%) remained plazomicin-susceptible.
CONCLUSION: Plazomicin demonstrated significantly greater in vitro activity than conventional aminoglycosides against CRE, but overall susceptibility remained limited. Its role in high-resistance Indian settings should be selective and guided by phenotypic susceptibility testing rather than empirical use.